Curanex Pharmaceuticals Inc (NASDAQ:CURX) Sees Significant Decline in Short Interest

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 449 shares, a decrease of 98.2% from the August 15th total of 24,375 shares. Based on an average trading volume of 35,024 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Curanex Pharmaceuticals Stock Up 2.6%

Shares of NASDAQ CURX traded up $0.11 during midday trading on Thursday, reaching $4.31. 24,177 shares of the stock were exchanged, compared to its average volume of 33,791. Curanex Pharmaceuticals has a twelve month low of $3.58 and a twelve month high of $183.59. The firm has a 50-day simple moving average of $4.36 and a two-hundred day simple moving average of $6.47. The firm has a market cap of $6.77 million and a price-to-earnings ratio of -0.55.

Hedge Funds Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new position in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 64,067 shares of the company’s stock, valued at approximately $46,000.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.